Compare First Trust NASDAQ Cybersecurity ETF (CIBR) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ Cybersecurity ETF vs Enveric Biosciences Inc — how do they compare? First Trust NASDAQ Cybersecurity ETF trades at $100.03, while Enveric Biosciences Inc trades at $1.55 (market cap $6.20M). The key difference: First Trust NASDAQ Cybersecurity ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| CIBR | ENVB | |
|---|---|---|
52-Week High | $100.60 | $17.40 |
52-Week Low | $60.74 | $1.27 |
Market Cap | — | $6.20M |
Sector | — | Health |
Enterprise Value | — | $1.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CIBR, the First Trust Nasdaq Cybersecurity ETF, trades at $97.85, up 1.51% on the day, with a bullish technical signal from moving averages. The ETF has shown strong performance, reportedly outperforming the S&P 500 by three to one year-to-date as of June 5, 2026 (24/7 Wall Street). Recent news highlights institutional activity, including Bank of America reducing its stake while First Trust Advisors increased its position.
The outlook for CIBR is positive, driven by growing cybersecurity spending exceeding $300 billion in 2026 and AI-driven demand. Risks include high concentration in tech stocks and market volatility. Analyst sentiment is optimistic, with upgrades citing reasonable valuations and secular growth trends.
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Trust NASDAQ Cybersecurity ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.
Read more on CIBR →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
